Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST).
Phase of Trial: Phase IV
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 20 Apr 2010 Actual patient number changed from 60 to 64 as reported by ClinicalTrials.gov.
- 13 Apr 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 13 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.